UK AMD EMR USERS GROUP REPORT V: Benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12

British Journal of Ophthalmology

Volumn 99, Issue 8, 2015, Pages 1045-1050

  Lee, Aaron Y ^a   Lee, Cecilia S ^b   Butt, Thomas ^c   Xing, Wen ^a   Johnston, Robert L ^d   Chakravarthy, Usha ^e   Egan, Catherine ^a   Akerele, Toks ^f   McKibbin, Martin ^g   Downey, Louise ^h   Natha, Salim ⁱ   Bailey, Clare ^j   Khan, Rehna ^k   Antcliff, Richard ^l   Varma, Atul ^m   Kumar, Vineeth ⁿ   Tsaloumas, Marie ^o   Mandal, Kaveri ^p   Liew, Gerald ^q   Keane, Pearse A ^a   Sim, Dawn ^a,c   Bunce, Catey ^a   Tufail, Adnan ^a   Armstrong, Stewart ^r   Cazabon, Joey ^r   Mohamed, Quresh ^r   Sallam, Ahmed ^r   Zarranz Ventura Hull, Javier ^r   Arora, Seema ^r   Cook, Helen ^r   Gopalakrishnan, Kala ^r   Lyon, Fiona ^r   Islam, Tahir ^r   Zaman, Naeem ^r   Backhouse, Oliver ^r   Dabbs, Tim ^r   Davies, Bryn ^r   Mokete, Bataung ^r   O'Neill, Damian ^r   Patel, Praveen J ^r   more..

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^e ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^f PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

ⁱ Wrightington Wigan and Leigh NHS Trust   (United Kingdom)

^j BRISTOL EYE HOSPITAL   (United Kingdom)

^k CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

^l ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^m MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

ⁿ WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

^o UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^p WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q UNIVERSITY OF SYDNEY   (Australia)

^r University of Sydney ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PRIORITY JOURNAL; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; TIME TO TREATMENT; UNITED KINGDOM; VISUAL ACUITY; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ELECTRONIC MEDICAL RECORD; FACTUAL DATABASE; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; GREAT BRITAIN; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84938751886     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306229     Document Type: Article

References (23)

1. Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95.
2. Congdon N, O'Colmain B, Klaver CCW, et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
3. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
4. National Institute of Clinical Excellence (NICE) technology appraisal guidance 155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. June, 2014. http://www. nice. org. uk/TA155
5. Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
6. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA StudyGroup. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
7. Keenan TDL, Kelly SP, Sallam A, et al. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol 2013;97:1168-72.
8. Zarranz-Ventura J, Liew G, Johnston RL, et al.; UK Age-related macular degeneration EMR Users Group. The neovascular age-related macular degeneration database: report 2: incidence, management and visual outcomes of second treated eyes. Ophthalmology 2014;121:1966-75. Article in press.
9. Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 2012;57:389-414.
10. Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
11. Owen CG, Fletcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-17.
12. Dawson SR, Mallen CD, Gouldstone MB, et al. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol 2014;14:78.
13. Slakter JS, Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol 2005;50:263-73.
14. Cruess AF, Zlateva G, Xu X, et al. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics 2008;26:57-73.
15. Oliver-Fernandez A, Bakal J, Segal S, et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005;40:313-19.
16. Weingessel B, Hintermayer G, Maca SM, et al. The significance of early treatment of exudative age-related macular degeneration: 12 months' results. Wien Klin Wochenschr 2012;124:750-5.
17. Canan H, Sizmaz S, Altan-Yaycioglu R, et al. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. Clin Interv Aging 2014;9:141-5.
18. Rofagha S, Bhisitkul RB, Boyer DS, et al.; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.
19. Muether PS, Hermann MM, Koch K, et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011;249:633-7.
20. Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013;251:453-8.
21. Chew EY, Clemons TE, Bressler SB, et al.; Appendix 1 for AREDS2-HOME Study Research Group. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design-HOME Study report number 1. Contemp Clin Trials 2014;37:294-300.
22. Group AHSR, Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014;121:535-44.
23. Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013;7:1849-58.